CANT1
CANT1 (Soluble calcium-activated nucleotidase 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.
Overview
Calcium-dependent nucleotidase with a preference for ribonucleosides diphosphate UDP, GDP and IDP, while having very low activity towards ADP and CDP. In vitro, it can also act with low or negligible efficiency on ribonucletides triphosphate UTP, GTP, ITP, ATP and CTP. Does not hydrolyse AMP and GMP.
IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Oesophageal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CANT1 (Soluble calcium-activated nucleotidase 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.
- 1 · What it is
CANT1 (Soluble calcium-activated nucleotidase 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer and Oesophageal and junctional adenocarcinoma.
- 2 · What goes wrong in cancer
Calcium-dependent nucleotidase with a preference for ribonucleosides diphosphate UDP, GDP and IDP, while having very low activity towards ADP and CDP.
- 3 · How drugs use it
No product in this corpus aims at CANT1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
External identifiers
Sources: HGNC HGNC:19721 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8WVQ1 (protein name, function text, keywords and locations (REST API)); IntOGen CANT1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Calcium-dependent nucleotidase with a preference for ribonucleosides diphosphate UDP, GDP and IDP, while having very low activity towards ADP and CDP. In vitro, it can also act with low or negligible efficiency on ribonucletides triphosphate UTP, GTP, ITP, ATP and CTP. Does not hydrolyse AMP and GMP. Involved in proteoglycan synthesis. Location: Endoplasmic reticulum membrane; Golgi apparatus, Golgi stack membrane; Cell membrane (UniProt). Locus 17q25.3 (HGNC).
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CANT1" OR ABSTRACT:"CANT1" OR TITLE:"calcium activated nucleotidase 1" OR ABSTRACT:"calcium activated nucleotidase 1" OR TITLE:"Soluble calcium-activated nucleotidase 1" OR ABSTRACT:"Soluble calcium-activated nucleotidase 1" OR TITLE:"SHAPY" OR ABSTRACT:"SHAPY" OR TITLE:"SCAN-1" OR ABSTRACT:"SCAN-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CANT1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZNF208
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetNUMA1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetTGFBR1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetCTNND2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetGRM3
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TrialMetabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.
- PersonJens Höppner
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer.